Home / Articles / Cationic radionuclides and ligands for targeted therapeutic radiopharmaceuticals

Cationic radionuclides and ligands for targeted therapeutic radiopharmaceuticals

Bayirta Vladimirovna Egorova 1
Bayirta Vladimirovna Egorova
, 
Olga Anatol'evna Fedorova 1, 2
Olga Anatol'evna Fedorova
, 
1 Lomonosov Moscow State University, Faculty of Chemistry
2 A. N. Nesmeyanov Institute of Organoelement Compounds of the Russian Academy of Sciences, Moscow
10.1070/RCR4890
Published 30 November 2018
Review , RCR4890, Volume 88, Issue 9, 901-924
20
Share
Cite this
GOST
 | 
Cite this
GOST
Copy cite
Egorova B. V., Fedorova O. A., Kalmykov S. N. Cationic radionuclides and ligands for targeted therapeutic radiopharmaceuticals // Russian Chemical Reviews. 2018. Vol. 88. No. 9. pp. 901-924.
GOST all authors (up to 50)
Copy cite
Egorova B. V., Fedorova O. A., Kalmykov S. N. Cationic radionuclides and ligands for targeted therapeutic radiopharmaceuticals // Russian Chemical Reviews. 2018. Vol. 88. No. 9. pp. 901-924.
RIS
 | 
Cite this
RIS
Copy cite
TY - JOUR
DO - 10.1070/RCR4890
UR - https://rcr.colab.ws/publications/10.1070/RCR4890
TI - Cationic radionuclides and ligands for targeted therapeutic radiopharmaceuticals
T2 - Russian Chemical Reviews
AU - Egorova, Bayirta Vladimirovna
AU - Fedorova, Olga Anatol'evna
AU - Kalmykov, Stepan Nikolaevich
PY - 2018
DA - 2018/11/30
PB - ANO Editorial Board of the journal Uspekhi Khimii
SP - 901-924
IS - 9
VL - 88
ER -
BibTex
 | 
Cite this
BibTex (up to 50 authors)
Copy cite
@article{2018_Egorova,
author = {Bayirta Vladimirovna Egorova and Olga Anatol'evna Fedorova and Stepan Nikolaevich Kalmykov},
title = {Cationic radionuclides and ligands for targeted therapeutic radiopharmaceuticals},
journal = {Russian Chemical Reviews},
year = {2018},
volume = {88},
publisher = {ANO Editorial Board of the journal Uspekhi Khimii},
month = {Nov},
url = {https://rcr.colab.ws/publications/10.1070/RCR4890},
number = {9},
pages = {901--924},
doi = {10.1070/RCR4890}
}
MLA
Cite this
MLA
Copy cite
Egorova, Bayirta Vladimirovna, et al. “Cationic radionuclides and ligands for targeted therapeutic radiopharmaceuticals.” Russian Chemical Reviews, vol. 88, no. 9, Nov. 2018, pp. 901-924. https://rcr.colab.ws/publications/10.1070/RCR4890.
Views / Visits / Downloads
25 / 24 / 4

Abstract

This review considers the already used and potential alpha- and beta-emitting cationic radionuclides for targeted radionuclide therapy. Recent results of laboratory, preclinical and clinical applications of these radionuclides are discussed. As opposed to beta-emitters, which are already used in nuclear medicine, alpha-emitters involved in targeted radiopharmaceuticals were subjected to clinical trials only recently and were found to be therapeutically effective. The review summarizes recent trends in the development of ligands as components of radiopharmaceuticals addressing specific features of short-lived cationic radionuclides applied in medicine. Despite a steadily growing number of chelating ligands, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and diethylenetriaminepentaacetic acid (DTPA) remain the most widely used agents in nuclear medicine. The drawbacks of these compounds restrict the application of radionuclides in medicine. Variations in the macrocycle size, the introduction and modification of substituents can significantly improve the chelating ability of ligands, enhance stability of radionuclide complexes with these ligands and eliminate the influence of ligands on the affinity of biological targeting vectors.

The bibliography includes 189 references.

Funders

Russian Science Foundation
18-73-10035

References

2.
First-in-human study of 177Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer
Zang J., Fan X., Wang H., Liu Q., Wang J., Li H., Li F., Jacobson O., Niu G., Zhu Z., Chen X.
European Journal of Nuclear Medicine and Molecular Imaging , 2018
3.
Linker Modification Strategies To Control the Prostate-Specific Membrane Antigen (PSMA)-Targeting and Pharmacokinetic Properties of DOTA-Conjugated PSMA Inhibitors
Benešová M., Bauder-Wüst U., Schäfer M., Klika K.D., Mier W., Haberkorn U., Kopka K., Eder M.
Journal of Medicinal Chemistry , 2016
5.
An Overview of Targeted Alpha Therapy with 225Actinium and 213Bismuth
Morgenstern A., Apostolidis C., Kratochwil C., Sathekge M., Krolicki L., Bruchertseifer F.
Current Radiopharmaceuticals , 2018
6.
Matching chelators to radiometals for radiopharmaceuticals
Price E.W., Orvig C.
Chemical Society Reviews , 2014
9.
Actinium-225 for Targeted α Therapy: Coordination Chemistry and Current Chelation Approaches
Thiele N.A., Wilson J.J.
Cancer Biotherapy and Radiopharmaceuticals , 2018
10.
rcr_88_9_901_bib10
Kassis
J. Nucl. Med. , 2005
11.
rcr_88_9_901_bib11
Roessler
1989
12.
rcr_88_9_901_bib12
Mindt
2011
13.
Production routes of the alpha emitting 149Tb for medical application
Beyer G.J., Čomor J.J., Daković M., Soloviev D., Tamburella C., Hagebø E., Allan B., Dmitriev S.N., Zaitseva N.G.
Radiochimica Acta , 2002
14.
Radiometals for Combined Imaging and Therapy
Cutler C.S., Hennkens H.M., Sisay N., Huclier-Markai S., Jurisson S.S.
Chemical Reviews , 2012
15.
rcr_88_9_901_bib15
Silberstein
2003
16.
Direct in vitro and in vivo comparison of 161Tb and 177Lu using a tumour-targeting folate conjugate
Müller C., Reber J., Haller S., Dorrer H., Bernhardt P., Zhernosekov K., Türler A., Schibli R.
European Journal of Nuclear Medicine and Molecular Imaging , 2013
18.
Targeted Alpha Therapy with 213Bi
Morgenstern A., Bruchertseifer F., Apostolidis C.
Current Radiopharmaceuticals , 2011
20.
rcr_88_9_901_bib20
Cotton
2006
22.
rcr_88_9_901_bib22
Cotton
2006
23.
Radiation doses of yttrium-90 citrate and yttrium-90 EDTMP as determined via analogous yttrium-86 complexes and positron emission tomography
R�sch F., Herzog H., Plag C., Neumaier B., Braun U., M�ller-G�rtnere H., St�cklin G.
European Journal of Nuclear Medicine and Molecular Imaging , 1996
24.
Peptide Receptor Radionuclide Therapy with 90Y-DOTATOC and 177Lu-DOTATOC in Advanced Neuroendocrine Tumors: Results from a Danish Cohort Treated in Switzerland
Pfeifer A.K., Gregersen T., Grønbæk H., Hansen C.P., Müller-Brand J., Herskind Bruun K., Krogh K., Kjær A., Knigge U.
Neuroendocrinology , 2011
25.
90Y-DOTATOC Dosimetry–Based Personalized Peptide Receptor Radionuclide Therapy
Menda Y., Madsen M.T., O’Dorisio T.M., Sunderland J.J., Watkins G.L., Dillon J.S., Mott S.L., Schultz M.K., Zamba G.K., Bushnell D.L., O’Dorisio M.S.
Journal of Nuclear Medicine , 2018
26.
rcr_88_9_901_bib26
27.
Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study.
Cwikla J.B., Sankowski A., Seklecka N., Buscombe J.R., Nasierowska-Guttmejer A., Jeziorski K.G., Mikolajczak R., Pawlak D., Stepien K., Walecki J.
Annals of Oncology , 2010
28.
Peptide receptor radionuclide therapy with 90Y-DOTATATE/90Y-DOTATOC in patients with progressive metastatic neuroendocrine tumours: assessment of response, survival and toxicity
Vinjamuri S., Gilbert T.M., Banks M., McKane G., Maltby P., Poston G., Weissman H., Palmer D.H., Vora J., Pritchard D.M., Cuthbertson D.J.
British Journal of Cancer , 2013
29.
End-stage renal disease after treatment with 90Y-DOTATOC
Cybulla M., Weiner S., Otte A.
European Journal of Nuclear Medicine and Molecular Imaging , 2001
30.
Yttrium-90 DOTATOC: first clinical results
Otte A., Herrmann R., Heppeler A., Behe M., Jermann E., Powell P., Maecke H.R., Muller J.
European Journal of Nuclear Medicine and Molecular Imaging , 1999
31.
Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study
Bodei L., Cremonesi M., Zoboli S., Grana C., Bartolomei M., Rocca P., Caracciolo M., Mäcke H.R., Chinol M., Paganelli G.
European Journal of Nuclear Medicine and Molecular Imaging , 2003
32.
A new internal pair production branching ratio of 90Y: the development of a non-destructive assay for 90Y and 90Sr.
Selwyn R.G., Nickles R.J., Thomadsen B.R., DeWerd L.A., Micka J.A.
Applied Radiation and Isotopes , 2007
33.
Internal Pair Production of 90Y Permits Hepatic Localization of Microspheres Using Routine PET: Proof of Concept
Gates V.L., Esmail A.A., Marshall K., Spies S., Salem R.
Journal of Nuclear Medicine , 2010
34.
rcr_88_9_901_bib34
Sartor
Rev. Urol. , 2004
35.
rcr_88_9_901_bib35
Tsyb
Sib. Oncol. J. , 2006
36.
Targeted alpha therapy in vivo: direct evidence for single cancer cell kill using 149Tb-rituximab
Beyer G.-., Miederer M., Vranješ-Đurić S., Čomor J.J., Künzi G., Hartley O., Senekowitsch-Schmidtke R., Soloviev D., Buchegger F.
European Journal of Nuclear Medicine and Molecular Imaging , 2004
37.
10.1667/0033-7587(2003)159[0612:COTROT]2.0.CO;2
38.
Folate Receptor Targeted Alpha-Therapy Using Terbium-149
Müller C., Reber J., Haller S., Dorrer H., Köster U., Johnston K., Zhernosekov K., Türler A., Schibli R.
Pharmaceuticals , 2014
39.
rcr_88_9_901_bib39
Müller
EJNMMI Radiopharm. Chem. , 2016
40.
The low-energy β− and electron emitter 161Tb as an alternative to 177Lu for targeted radionuclide therapy
Lehenberger S., Barkhausen C., Cohrs S., Fischer E., Grünberg J., Hohn A., Köster U., Schibli R., Türler A., Zhernosekov K.
Nuclear Medicine and Biology , 2011
41.
Auger radiation targeted into DNA: a therapy perspective
Buchegger F., Perillo-Adamer F., Dupertuis Y.M., Bischof Delaloye A.
European Journal of Nuclear Medicine and Molecular Imaging , 2006
42.
Contribution of Auger/conversion electrons to renal side effects after radionuclide therapy: preclinical comparison of 161Tb-folate and 177Lu-folate
Haller S., Pellegrini G., Vermeulen C., van der Meulen N.P., Köster U., Bernhardt P., Schibli R., Müller C.
EJNMMI Research , 2016
43.
Evaluation in vitro and in rats of161Tb-DTPA-octreotide, a somatostatin analogue with potential for intraoperative scanning and radiotherapy
de Jong M., Breeman W.A., Bernard B.F., Rolleman E.J., Hoflande L.J., Visser T.J., Setyono-Han B., Bakker W.H., van der Pluijm M.E., Krenning E.P.
European Journal of Nuclear Medicine and Molecular Imaging , 1995
45.
Lutetium-labelled peptides for therapy of neuroendocrine tumours
Kam B.L., Teunissen J.J., Krenning E.P., de Herder W.W., Khan S., van Vliet E.I., Kwekkeboom D.J.
European Journal of Nuclear Medicine and Molecular Imaging , 2012
46.
Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate
Kwekkeboom D.J., Bakker W.H., Kam B.L., Teunissen J.J., Kooij P.P., Herder W.W., Feelders R.A., Eijck C.H., Jong M., Srinivasan A., Erion J.L., Krenning E.P.
European Journal of Nuclear Medicine and Molecular Imaging , 2003
47.
Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival.
Kwekkeboom D.J., de Herder W.W., Kam B.L., van Eijck C.H., van Essen M., Kooij P.P., Feelders R.A., van Aken M.O., Krenning E.P.
Journal of Clinical Oncology , 2008
48.
Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study
Bodei L., Cremonesi M., Grana C.M., Fazio N., Iodice S., Baio S.M., Bartolomei M., Lombardo D., Ferrari M.E., Sansovini M., Chinol M., Paganelli G.
European Journal of Nuclear Medicine and Molecular Imaging , 2011
49.
rcr_88_9_901_bib49
de Jong
J. Nucl. Med. , 2005
50.
rcr_88_9_901_bib50
Forrer
J. Nucl. Med. , 2005
51.
Cyclotron Production of High Specific Activity 186gRe for Metabolic Radiotherapy
European Journal of Nuclear Medicine and Molecular Imaging , 2007
52.
177Lu-AMBA Biodistribution, Radiotherapeutic Efficacy, Imaging, and Autoradiography in Prostate Cancer Models with Low GRP-R Expression
Maddalena M.E., Fox J., Chen J., Feng W., Cagnolini A., Linder K.E., Tweedle M.F., Nunn A.D., Lantry L.E.
Journal of Nuclear Medicine , 2009
54.
Comparative studies of 177Lu-EDTMP and 177Lu-DOTMP as potential agents for palliative radiotherapy of bone metastasis.
Chakraborty S., Das T., Sarma H.D., Venkatesh M., Banerjee S.
Applied Radiation and Isotopes , 2008
55.
177Lu-EDTMP for palliation of pain from bone metastases in patients with prostate and breast cancer: a phase II study
Agarwal K.K., Singla S., Arora G., Bal C.
European Journal of Nuclear Medicine and Molecular Imaging , 2014
58.
Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy
Emmett L., Willowson K., Violet J., Shin J., Blanksby A., Lee J.
Journal of Medical Radiation Sciences , 2017
59.
Bone Marrow Recovery and Subsequent Chemotherapy Following Radiolabeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 in Men with Metastatic Castration-Resistant Prostate Cancer
Tagawa S.T., Akhtar N.H., Nikolopoulou A., Kaur G., Robinson B., Kahn R., Vallabhajosula S., Goldsmith S.J., Nanus D.M., Bander N.H.
Frontiers in Oncology , 2013
60.
Production of actinium, thorium and radium isotopes from natural thorium irradiated with protons up to 141 MeV
Ermolaev S.V., Zhuikov B.L., Kokhanyuk V.M., Matushko V.L., Kalmykov S.N., Aliev R.A., Tananaev I.G., Myasoedov B.F.
Radiochimica Acta , 2012
61.
Production of 225Ac and 223Ra by irradiation of Th with accelerated protons
Zhuikov B.L., Kalmykov S.N., Ermolaev S.V., Aliev R.A., Kokhanyuk V.M., Matushko V.L., Tananaev I.G., Myasoedov B.F.
Radiochemistry , 2011
63.
rcr_88_9_901_bib63
Finn
Blood , 2017
65.
Preclinical Evaluation of the α-Particle Generator Nuclide 225Ac for Somatostatin Receptor Radiotherapy of Neuroendocrine Tumors
Miederer M., Henriksen G., Alke A., Mossbrugger I., Quintanilla-Martinez L., Senekowitsch-Schmidtke R., Essler M.
Clinical Cancer Research , 2008
66.
PMPA for Nephroprotection in PSMA-Targeted Radionuclide Therapy of Prostate Cancer
Kratochwil C., Giesel F.L., Leotta K., Eder M., Hoppe-Tich T., Youssoufian H., Kopka K., Babich J.W., Haberkorn U.
Journal of Nuclear Medicine , 2015
68.
Phase I Trial of Targeted Alpha-Particle Therapy with Actinium-225 (225Ac)-Lintuzumab and Low-Dose Cytarabine (LDAC) in Patients Age 60 or Older with Untreated Acute Myeloid Leukemia (AML)
Jurcic J.G., Levy M.Y., Park J.H., Ravandi F., Perl A.E., Pagel J.M., Smith B.D., Estey E.H., Kantarjian H., Cicic D., Scheinberg D.A.
Blood , 2016
69.
Renal uptake of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody
Schwartz J., Jaggi J.S., O’Donoghue J.A., Ruan S., McDevitt M., Larson S.M., Scheinberg D.A., Humm J.L.
Physics in Medicine and Biology , 2011
71.
Mitigation of radiation nephropathy after internal α-particle irradiation of kidneys
Jaggi J.S., Seshan S.V., McDevitt M.R., Sgouros G., Hyjek E., Scheinberg D.A.
International Journal of Radiation Oncology Biology Physics , 2006
72.
Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial
Cordier D., Forrer F., Bruchertseifer F., Morgenstern A., Apostolidis C., Good S., Müller-Brand J., Mäcke H., Reubi J.C., Merlo A.
European Journal of Nuclear Medicine and Molecular Imaging , 2010
73.
Targeted α particle immunotherapy for myeloid leukemia
Jurcic J.G., Larson S.M., Sgouros G., McDevitt M.R., Finn R.D., Divgi C.R., Ballangrud Å.M., Hamacher K.A., Ma D., Humm J.L., Brechbiel M.W., Molinet R., Scheinberg D.A.
Blood , 2002
74.
Sequential Cytarabine and α-Particle Immunotherapy with Bismuth-213–Lintuzumab (HuM195) for Acute Myeloid Leukemia
Rosenblat T.L., McDevitt M.R., Mulford D.A., Pandit-Taskar N., Divgi C.R., Panageas K.S., Heaney M.L., Chanel S., Morgenstern A., Sgouros G., Larson S.M., Scheinberg D.A., Jurcic J.G.
Clinical Cancer Research , 2010
75.
Analysis of patient survival in a Phase I trial of systemic targeted α-therapy for metastatic melanoma
Allen B.J., Singla A.A., Rizvi S.M., Graham P., Bruchertseifer F., Apostolidis C., Morgenstern A.
Immunotherapy , 2011
76.
Interim analysis of toxicity and response in phase 1 trial of systemic targeted alpha therapy for metastatic melanoma
Raja C., Graham P., Rizvi S., Song E., Goldsmith H., Thompson J., Bosserhoff A., Morgenstern A., Apostolidis C., Kearsley J., Reisfeld R., Allen B.J.
Cancer Biology and Therapy , 2007
77.
Treatment of carcinoma in situ of the urinary bladder with an alpha-emitter immunoconjugate targeting the epidermal growth factor receptor: a pilot study
Autenrieth M.E., Seidl C., Bruchertseifer F., Horn T., Kurtz F., Feuerecker B., D’Alessandria C., Pfob C., Nekolla S., Apostolidis C., Mirzadeh S., Gschwend J.E., Schwaiger M., Scheidhauer K., Morgenstern A., et. al.
European Journal of Nuclear Medicine and Molecular Imaging , 2018
78.
Bismuth(III) complexes with aminopolycarboxylate and polyaminopolycarboxylate ligands: Chemistry and structure
Stavila V., Davidovich R.L., Gulea A., Whitmire K.H.
Coordination Chemistry Reviews , 2006
79.
rcr_88_9_901_bib79
Baes
1976
80.
Automated two column generator systems for medical radionuclides
McAlister D.R., Philip Horwitz E.
Applied Radiation and Isotopes , 2009
81.
213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience
Kratochwil C., Giesel F.L., Bruchertseifer F., Mier W., Apostolidis C., Boll R., Murphy K., Haberkorn U., Morgenstern A.
European Journal of Nuclear Medicine and Molecular Imaging , 2014
82.
213Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer
Sathekge M., Knoesen O., Meckel M., Modiselle M., Vorster M., Marx S.
European Journal of Nuclear Medicine and Molecular Imaging , 2017
83.
Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias
Burke J.M., Caron P.C., Papadopoulos E.B., Divgi C.R., Sgouros G., Panageas K.S., Finn R.D., Larson S.M., O'Reilly R.J., Scheinberg D.A., Jurcic J.G.
Bone Marrow Transplantation , 2003
84.
Tumour anti-vascular alpha therapy: a mechanism for the regression of solid tumours in metastatic cancer.
Allen B.J., Raja C., Rizvi S., Song E.Y., Graham P.
Physics in Medicine and Biology , 2007
85.
rcr_88_9_901_bib85
Tan
Int. J. Oncol. , 2012
86.
Gene expression profiling upon 212Pb-TCMC-trastuzumab treatment in the LS-174T i.p. xenograft model
Yong K.J., Milenic D.E., Baidoo K.E., Kim Y., Brechbiel M.W.
Cancer Medicine , 2013
87.
Melanoma Therapy via Peptide-Targeted α-Radiation
Miao Y., Hylarides M., Fisher D.R., Shelton T., Moore H., Wester D.W., Fritzberg A.R., Winkelmann C.T., Hoffman T., Quinn T.P.
Clinical Cancer Research , 2005
88.
rcr_88_9_901_bib88
Meredith
J. Nucl. Med. , 2015
89.
Dose Escalation and Dosimetry of First-in-Human α Radioimmunotherapy with 212Pb-TCMC-Trastuzumab
Meredith R., Torgue J., Shen S., Fisher D.R., Banaga E., Bunch P., Morgan D., Fan J., Straughn J.M.
Journal of Nuclear Medicine , 2014
90.
Pharmacokinetics and imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patients.
Meredith R.F., Torgue J., Azure M.T., Shen S., Saddekni S., Banaga E., Carlise R., Bunch P., Yoder D., Alvarez R.
Cancer Biotherapy and Radiopharmaceuticals , 2013
91.
Methodology for labeling proteins and peptides with lead-212 (212Pb)
Baidoo K.E., Milenic D.E., Brechbiel M.W.
Nuclear Medicine and Biology , 2013
92.
Preparation of 212Pb-labeled monoclonal antibody using a novel 224Ra-based generator solution.
Westrøm S., Generalov R., Bønsdorff T.B., Larsen R.H.
Nuclear Medicine and Biology , 2017
93.
Automated cassette-based production of high specific activity [203/212Pb]peptide-based theranostic radiopharmaceuticals for image-guided radionuclide therapy for cancer.
Li M., Zhang X., Quinn T.P., Lee D., Liu D., Kunkel F., Zimmerman B.E., McAlister D., Olewein K., Menda Y., Mirzadeh S., Copping R., Johnson F.L., Schultz M.K.
Applied Radiation and Isotopes , 2017
94.
Evaluation of potential chelating agents for radium.
Henriksen G., Hoff P., Larsen R.H.
Applied Radiation and Isotopes , 2002
95.
The Radiochemical and Radiopharmaceutical Applications of Radium
Gott M., Steinbach J., Mamat C.
Open Chemistry , 2016
96.
Nanozeolite bioconjugates labeled with 223 Ra for targeted alpha therapy
Piotrowska A., Męczyńska-Wielgosz S., Majkowska-Pilip A., Koźmiński P., Wójciuk G., Cędrowska E., Bruchertseifer F., Morgenstern A., Kruszewski M., Bilewicz A.
Nuclear Medicine and Biology , 2017
97.
rcr_88_9_901_bib97
Martell
1996
98.
Bifunctional Chelators for Therapeutic Lanthanide Radiopharmaceuticals
Liu S., Edwards D.S.
Bioconjugate Chemistry , 2000
99.
Equilibrium, 1H and 13C NMR Spectroscopy, and X-ray Diffraction Studies on the Complexes Bi(DOTA)- and Bi(DO3A-Bu)
Csajbók É., Baranyai Z., Bányai I., Brücher E., Király R., Müller-Fahrnow A., Platzek J., Radüchel B., Schäfer M.
Inorganic Chemistry , 2003
100.
DTPA complexation of bismuth in human blood serum.
Montavon G., Le Du A., Champion J., Rabung T., Morgenstern A.
Dalton Transactions , 2012
101.
rcr_88_9_901_bib101
Parker
1994
102.
Crystal structure and solution dynamics of the lutetium(III) chelate of DOTA
Aime S., Barge A., Botta M., Fasano M., Danilo Ayala J., Bombieri G.
Inorganica Chimica Acta , 1996
104.
Solution dynamics and stability of lanthanide(III) (S)-2-(p-nitrobenzyl)DOTA complexes.
Woods M., Kovacs Z., Kiraly R., Brücher E., Zhang S., Sherry A.D.
Inorganic Chemistry , 2004
106.
rcr_88_9_901_bib106
Chang
1993
108.
On the consequences of the stereochemical activity of the Bi(iii) 6s2 lone pair in cyclen-based complexes. The [Bi(DO3A)] case.
Pujales-Paradela R., Rodríguez-Rodríguez A., Gayoso-Padula A., Brandariz I., Valencia L., Esteban-Gómez D., Platas-Iglesias C.
Dalton Transactions , 2018
110.
rcr_88_9_901_bib110
Jang
1999
112.
rcr_88_9_901_bib112
Kukis
J. Nucl. Med. , 1998
116.
Design and synthesis of 225Ac radioimmunopharmaceuticals
McDevitt M.R., Ma D., Simon J., Frank R.K., Scheinberg D.A.
Applied Radiation and Isotopes , 2002
118.
rcr_88_9_901_bib118
Brouwers
J. Nucl. Med. , 2004
119.
213Bi-[DOTA0, Tyr3]Octreotide Peptide Receptor Radionuclide Therapy of Pancreatic Tumors in a Preclinical Animal Model
Norenberg J.P., Krenning B.J., Konings I.R., Kusewitt D.F., Nayak T.K., Anderson T.L., de Jong M., Garmestani K., Brechbiel M.W., Kvols L.K.
Clinical Cancer Research , 2006
120.
Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN).
Wild D., Frischknecht M., Zhang H., Morgenstern A., Bruchertseifer F., Boisclair J., Provencher-Bolliger A., Reubi J., Maecke H.R.
Cancer Research , 2011
123.
rcr_88_9_901_bib123
Kumar
1989
124.
The Chemical Fate of 212Bi-DOTA Formed by β- Decay of 212Pb(DOTA)2-***
Mirzadeh S., Kumar K., Gansow O.A.
Radiochimica Acta , 1993
125.
The use of 212Pb-labeled monoclonal antibody in the treatment of murine erythroleukemia.
Ruble G., Wu C., Squire R.A., Gansow O.A., Strand M.
International Journal of Radiation Oncology Biology Physics , 1996
128.
Synthesis, characterization, and evaluation of a novel bifunctional chelating agent for the lead isotopes 203Pb and 212Pb.
Chappell L.L., Dadachova E., Milenic D.E., Garmestani K., Wu C., Brechbiel M.W.
Nuclear Medicine and Biology , 2000
130.
rcr_88_9_901_bib130
Baranyai
2007
132.
rcr_88_9_901_bib132
Barge
2003
135.
Synthesis and biological evaluation of a novel decadentate ligand DEPA
Chong H., Lim S., Baidoo K.E., Milenic D.E., Ma X., Jia F., Song H.A., Brechbiel M.W., Lewis M.R.
Bioorganic and Medicinal Chemistry Letters , 2008
136.
Synthesis and comparative biological evaluation of bifunctional ligands for radiotherapy applications of (90)Y and (177)Lu.
Chong H., Sun X., Chen Y., Sin I., Kang C.S., Lewis M.R., Liu D., Ruthengael V.C., Zhong Y., Wu N., Song H.A.
Bioorganic and Medicinal Chemistry , 2015
138.
Synthesis and evaluation of a bifunctional chelate for development of Bi(III)-labeled radioimmunoconjugates
Dadwal M., Kang C.S., Song H.A., Sun X., Dai A., Baidoo K.E., Brechbiel M.W., Chong H.
Bioorganic and Medicinal Chemistry Letters , 2011
139.
Efficient Bifunctional Decadentate Ligand 3p-C-DEPA for Targeted α-Radioimmunotherapy Applications
Song H.A., Kang C.S., Baidoo K.E., Milenic D.E., Chen Y., Dai A., Brechbiel M.W., Chong H.
Bioconjugate Chemistry , 2011
141.
rcr_88_9_901_bib141
Sherry
J. Magn. Reson. , 1986
145.
Novel bimodal bifunctional ligands for radioimmunotherapy and targeted MRI.
Chong H., Song H.A., Ma X., E. Milenic D., D. Brady E., Lim S., Lee H., Baidoo K., Cheng D., Brechbiel M.W.
Bioconjugate Chemistry , 2008
146.
Efficient synthesis and evaluation of bimodal ligand NETA
Chong H., Song H.A., Birch N., Le T., Lim S., Ma X.
Bioorganic and Medicinal Chemistry Letters , 2008
147.
Jowsey J., Rowland R.E., Marshall J.H.
Radiation Research , 1958
149.
Synthesis and evaluation of a new bifunctional NETA chelate for molecular targeted radiotherapy using(90)Y or(177)Lu.
Kang C.S., Chen Y., Lee H., Liu D., Sun X., Kweon J., Lewis M.R., Chong H.
Nuclear Medicine and Biology , 2015
151.
Improved in vivo stability of actinium-225 macrocyclic complexes.
Deal K.A., Davis I.A., Mirzadeh S., Kennel S.J., Brechbiel M.W.
Journal of Medicinal Chemistry , 1999
153.
Comparison of 64Cu-Complexing Bifunctional Chelators for Radioimmunoconjugation: Labeling Efficiency, Specific Activity, and in Vitro/in Vivo Stability
Cooper M.S., Ma M.T., Sunassee K., Shaw K.P., Williams J.D., Paul R.L., Donnelly P.S., Blower P.J.
Bioconjugate Chemistry , 2012
154.
rcr_88_9_901_bib154
Hnatowich
J. Nucl. Med. , 1985
155.
rcr_88_9_901_bib155
Camera
J. Nucl. Med. , 1994
156.
rcr_88_9_901_bib156
Ruegg
Cancer Res. , 1990
160.
rcr_88_9_901_bib160
Brechbiel
1991
161.
In vivo evaluation of bismuth-labeled monoclonal antibody comparing DTPA-derived bifunctional chelates.
Milenic D.E., Roselli M., Mirzadeh S., Pippin C.G., Gansow O.A., Colcher D., Brechbiel M.W., Schlom J.
Cancer Biotherapy and Radiopharmaceuticals , 2002
162.
Physical Parameters and Biological Stability of Yttrium(III) Diethylenetriaminepentaacetic Acid Derivative Conjugates
McMurry T.J., Pippin C.G., Wu C., Deal K.A., Brechbiel M.W., Mirzadeh S., Gansow O.A.
Journal of Medicinal Chemistry , 1998
163.
A systematic comparative evaluation of 90Y-labeled bifunctional chelators for their use in targeted therapy.
Chakravarty R., Chakraborty S., Dash A.
Journal of Labelled Compounds and Radiopharmaceuticals , 2013
164.
Stereochemical influence on the stability of radio-metal complexes in vivo. Synthesis and evaluation of the four stereoisomers of 2-(p-nitrobenzyl)-trans-CyDTPA.
Wu C., Kobayashi H., Sun B., Yoo T.M., Paik C.H., Gansow O.A., Carrasquillo J.A., Pastan I., Brechbiel M.W.
Bioorganic and Medicinal Chemistry , 1997
165.
PET imaging of tumor angiogenesis in mice with VEGF‐A–targeted 86Y‐CHX‐A″‐DTPA‐bevacizumab
Nayak T.K., Garmestani K., Baidoo K.E., Milenic D.E., Brechbiel M.W.
International Journal of Cancer , 2010
167.
In Vivo Biodistribution, PET Imaging, and Tumor Accumulation of 86Y- and 111In-Antimindin/RG-1, Engineered Antibody Fragments in LNCaP Tumor–Bearing Nude Mice
Schneider D.W., Heitner T., Alicke B., Light D.R., McLean K., Satozawa N., Parry G., Yoo J., Lewis J.S., Parry R.
Journal of Nuclear Medicine , 2009
168.
Melanoma imaging using (111)In-, (86)Y- and (68)Ga-labeled CHX-A''-Re(Arg11)CCMSH.
Wei L., Zhang X., Gallazzi F., Miao Y., Jin X., Brechbiel M.W., Xu H., Clifford T., Welch M.J., Lewis J.S., Quinn T.P.
Nuclear Medicine and Biology , 2009
169.
In vitro and in vivo evaluation of novel ligands for radioimmunotherapy
Chong H., Milenic D.E., Garmestani K., Brady E.D., Arora H., Pfiester C., Brechbiel M.W.
Nuclear Medicine and Biology , 2006
170.
Anti-EGFRvIII monoclonal antibody armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands.
Hens M., Vaidyanathan G., Zhao X., Bigner D.D., Zalutsky M.R.
Nuclear Medicine and Biology , 2010
171.
In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications.
Milenic D.E., Garmestani K., Chappell L.L., Dadachova E., Yordanov A., Ma D., Schlom J., Brechbiel M.W.
Nuclear Medicine and Biology , 2002
172.
Antitenascin antibody 81C6 armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands
Yordanov A.T., Hens M., Pegram C., Bigner D.D., Zalutsky M.R.
Nuclear Medicine and Biology , 2007
173.
H(4)octapa-trastuzumab: versatile acyclic chelate system for 111In and 177Lu imaging and therapy.
Price E.W., Zeglis B.M., Cawthray J.F., Ramogida C.F., Ramos N., Lewis J.S., Adam M.J., Orvig C.
Journal of the American Chemical Society , 2013
174.
rcr_88_9_901_bib174
de Guadalupe Jaraquemada-Peláez
Dalton Trans. , 2017
175.
rcr_88_9_901_bib175
Comba
Chem. – Eur. J. , 2017
176.
An Eighteen‐Membered Macrocyclic Ligand for Actinium‐225 Targeted Alpha Therapy
Thiele N.A., Brown V., Kelly J.M., Amor‐Coarasa A., Jermilova U., MacMillan S.N., Nikolopoulou A., Ponnala S., Ramogida C.F., Robertson A.K., Rodríguez‐Rodríguez C., Schaffer P., Williams C., Babich J.W., Radchenko V., et. al.
Angewandte Chemie - International Edition , 2017
177.
What a Difference a Carbon Makes: H4octapa vs H4C3octapa, Ligands for In-111 and Lu-177 Radiochemistry
Price E.W., Zeglis B.M., Cawthray J.F., Lewis J.S., Adam M.J., Orvig C.
Inorganic Chemistry , 2014
178.
Stability, Water Exchange, and Anion Binding Studies on Lanthanide(III) Complexes with a Macrocyclic Ligand Based on 1,7-Diaza-12-crown-4: Extremely Fast Water Exchange on the Gd3+ Complex
Pálinkás Z., Roca-Sabio A., Mato-Iglesias M., Esteban-Gómez D., Platas-Iglesias C., de Blas A., Rodríguez-Blas T., Tóth É.
Inorganic Chemistry , 2009
179.
rcr_88_9_901_bib179
Ferreirós-Martínez
Inorg. Chem. , 2009
180.
Macrocyclic Receptor Exhibiting Unprecedented Selectivity for Light Lanthanides
Roca-Sabio A., Mato-Iglesias M., Esteban-Gómez D., Tóth É., Blas A.D., Platas-Iglesias C., Rodríguez-Blas T.
Journal of the American Chemical Society , 2009
181.
H2Me-do2pa: an attractive chelator with fast, stable and inert natBi3+ and 213Bi3+ complexation for potential α-radioimmunotherapy applications
Lima L.M., Beyler M., Oukhatar F., Le Saec P., Faivre-Chauvet A., Platas-Iglesias C., Delgado R., Tripier R.
Chemical Communications , 2014
182.
Investigating the Complexation of the Pb2+/Bi3+ Pair with Dipicolinate Cyclen Ligands
Lima L.M., Beyler M., Delgado R., Platas-Iglesias C., Tripier R.
Inorganic Chemistry , 2015
183.
Potentiometric studies of complex formation of amidopyridine macrocycles bearing pendant arms with proton and heavy metal ions in aqueous solution
Fedorov Y.V., Fedorova O.A., Kalmykov S.N., Oshchepkov M.S., Nelubina Y.V., Arkhipov D.E., Egorova B.V., Zubenko A.D.
Polyhedron , 2017
184.
Equilibrium and formation/dissociation kinetics of some Ln(III)PCTA complexes.
Tircsó G., Kovács Z., Sherry A.D.
Inorganic Chemistry , 2006
185.
Novel pyridine-containing azacrown-ethers for the chelation of therapeutic bismuth radioisotopes: Complexation study, radiolabeling, serum stability and biodistribution
Egorova B.V., Matazova E.V., Mitrofanov A.A., Aleshin G.Y., Trigub A.L., Zubenko A.D., Fedorova O.A., Fedorov Y.V., Kalmykov S.N.
Nuclear Medicine and Biology , 2018
186.
Complexation of Bi3+, Ac3+, Y3+, Lu3+, La3+ and Eu3+ with benzo-diaza-crown ether with carboxylic pendant arms
Egorova B.V., Oshchepkov M.S., Fedorov Y.V., Fedorova O.A., Budylin G.S., Shirshin E.A., Kalmykov S.N.
Radiochimica Acta , 2016
187.
(S)-5-(p-nitrobenzyl)-PCTA, a promising bifunctional ligand with advantageous metal ion complexation kinetics.
Tircsó G., Benyó E.T., Suh E.H., Jurek P., Kiefer G.E., Sherry A.D., Kovács Z.
Bioconjugate Chemistry , 2009
188.
A systematic evaluation of the potential of PCTA-NCS ligand as a bifunctional chelating agent for design of 177Lu radiopharmaceuticals
Pandey U., Gamre N., Kumar Y., Shetty P., Sarma H.D., Dash A.
Journal of Radioanalytical and Nuclear Chemistry , 2015
189.
Immuno-PET Imaging and Radioimmunotherapy of 64Cu-/177Lu-Labeled Anti-EGFR Antibody in Esophageal Squamous Cell Carcinoma Model
Song I.H., Lee T.S., Park Y.S., Lee J.S., Lee B.C., Moon B.S., An G.I., Lee H.W., Kim K.I., Lee Y.J., Kang J.H., Lim S.M.
Journal of Nuclear Medicine , 2016